The risk of cardiovascular complications with current obesity drugs
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The risk of cardiovascular complications with current obesity drugs
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2020-08-05
DOI
10.1080/14740338.2020.1806234
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
- (2020) Abhinav Sharma et al. CIRCULATION
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL‐IBT Program
- (2019) Thomas A. Wadden et al. Obesity
- Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology
- (2019) Ariana M. Chao et al. Obesity
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Cardiovascular biomarkers in clinical studies of type 2 diabetes
- (2018) Maria P. A. Baldassarre et al. DIABETES OBESITY & METABOLISM
- Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
- (2018) Rohan Khera et al. GASTROENTEROLOGY
- Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
- (2018) Sadiya S. Khan et al. JAMA Cardiology
- Cardiovascular Safety During and After Use of Phentermine and Topiramate
- (2018) Mary E Ritchey et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial
- (2018) Thomas A. Wadden et al. Obesity
- Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
- (2017) James L. Januzzi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mechanisms, Pathophysiology, and Management of Obesity
- (2017) Steven B. Heymsfield et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
- (2016) Igho J. Onakpoya et al. BMC Medicine
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
- (2016) Catherine E. Thomas et al. Obesity
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010
- (2015) Ying Xia et al. Obesity
- Cardiovascular effects of phentermine and topiramate
- (2014) Jens Jordan et al. JOURNAL OF HYPERTENSION
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Body Mass Index and Risk of Incident Hypertension Over the Life Course
- (2012) Hasan M. Shihab et al. CIRCULATION
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- The Pharmacological Treatment and Management of Obesity
- (2011) Syed Sufyan Hussain et al. POSTGRADUATE MEDICINE
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Rational Design of a Combination Medication for the Treatment of Obesity
- (2008) Frank L. Greenway et al. Obesity
- Sibutramine-associated adverse effects: a practical guide for its safe use
- (2007) M. Florentin et al. Obesity Reviews
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now